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Abstract 
The efficacy of medicines, medical devices, and other health technologies should be proved in trials 
that assess final patient-relevant outcomes such as survival or morbidity. However, market access 
and coverage decisions are often based on surrogate endpoints, biomarkers, or intermediate 
endpoints, which aim to substitute and predict patient-relevant outcomes that are unavailable due to 
methodological, financial, or practical constraints. We provide a summary of the current use of 
surrogate endpoints in healthcare policy, discussing the case for and against their adoption and 
reviewing validation methods. We introduce a three-step framework for policy makers to handle 
surrogates, which involves establishing the level of evidence, assessing the strength of the 
association, and quantifying relations between surrogates and final outcomes. Although use of 
surrogates can be problematic, they can, when selected and validated appropriately, offer important 
opportunities for more efficient clinical trials and faster access to new health technologies that benefit 
patients and healthcare systems.  
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Introduction  
Market access and coverage policies for drugs, medical devices, and other health technologies ideally 
should be based on randomised controlled trials or systematic reviews of randomised controlled trials 
that assess final outcomes relevant to patients, such as survival, morbidity, and health-related quality 
of life.1 Nevertheless, regulatory agencies, including the Food and Drug Administration (FDA) in the 
United States and the European Medicines Agency (EMA), have a long tradition of licensing 
technologies based solely on evidence of their effects on biomarkers or intermediate endpoints that 
act as so-called surrogate endpoints (Table 1).2-4 The role of surrogates is becoming increasingly 
important in the context of programmes initiated by the FDA and EMA to offer accelerated approval to 
promising new medicines. The key rationale for the use of a surrogate endpoint is to predict the 
benefits of treatment in the absence of data on patient-relevant final outcomes.5 Evidence from 
surrogate endpoints may not only expedite the regulatory approval of new health technologies but 
also inform coverage and reimbursement decisions. In the United Kingdom (UK), the National Institute 
for Health and Care Excellence (NICE) has made several recommendations based on cost-
effectiveness analyses that relied entirely on treatment effects derived from clinical trials that 
assessed surrogate endpoints.6  
 
<<table 1 near here>> 
 
Despite their potential appeal, the use of surrogates remains controversial, because they may not 
capture the combined risk-benefit profile of a technology and because superiority on a surrogate 
endpoint may not translate into benefits for patients, or if it did the healthcare system may not judge 
the benefits to be good value for money.7-10 These limitations can be illustrated by the examples of 
two surrogate endpoints used in oncology and considered by FDA, as a licensing body, and NICE, as 
a reimbursement body, in their decision-making activity.  
In May 2003, the FDA approved the tyrosine-kinase inhibitor gefitinib for patients with non-small-cell 
lung cancer based on a favourable effect of the drug on the surrogate endpoint of the rate of tumour 
response.11 The initial approved indication was the treatment of patients who were refractory to 
established cancer treatments²both a platinum-based regimen and docetaxel.12,13 However, data 
from two randomised studies of gefitinib vs placebo that showed no significant survival benefit 
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became available in 2005,14,15 and the FDA consequently released new labelling for gefitinib, which 
limited its use only to continuation in patients who had already taken the medicine for the disease and 
whose doctor believed it was helping them.16  
In a second example, the EMA approved the second-generation tyrosine-kinase inhibitor dasatinib for 
treatment of the ³chronic phase´ of chronic myeloid leukaemia (CML) in patients who were newly 
diagnosed and positive for the Philadelphia chromosome.17 This approval was based on data from a 
randomised controlled trial that showed the relative efficacy of dasatinib compared with imatinib on 
the primary endpoint of confirmed complete cytogenetic response (CCR, surrogate outcome) by 12 
months (e.g. 77% vs 66%, p=0·007).18 However, in deciding about approval of new products, EMA 
considers their benefit/risk profile, while decisions of Health Technology Assessment (HTA) bodies 
and payers such as NICE and the Centers for Medicare and Medicaid Services in the United States 
are based on a broader value for money evaluation. When NICE appraised the drug in March 2012, it 
concluded that first-line use of dasatinib for the treatment of chronic myeloid leukaemia represented 
poor value for money. In a situation where clinical effectiveness information was only available either 
in terms of biomarker endpoints or as immature data on overall survival, the evidence review group 
systematically looked for evidence supporting the adoption of CCR at 12 months as reliable predictors 
of overall survival by looking at tyrosine kinase inhibitor (TKI)-treated patients data, naïve to previous 
pharmacological therapies for CML. Historical data of mid-term survival (i.e., up to 7 years since the 
start of the treatment), conditional to achievement of CCR at 12 months post-treatment were identified 
and used to predict and extrapolate long-term survival curves for dasatinib treated cohort of patients. 
The analyses showed a small estimated incremental gain in survival (final outcome) extrapolated from 
the observed improvement on CCR (22·7 years vs 21·3 years) and a patient cost of £30 477 per year, 
which equated to a cost per quality-adjusted life-year (QALY) of more than £200 000.19  
 
As the issues introduced are likely to intensify in a context of promotion of accelerated approval for 
medicines, raising greater challenges for those bodies seeking to assess the costs and benefits of 
new health technologies, in this policy perspective we discuss the case for and against the use of 
surrogate endpoints, give an overview of methods to validate the selection of surrogates, and propose 
a framework for the appropriate use of surrogates by policy makers. Finally, we identify unanswered 
questions and key areas for future research. 
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The case for surrogate endpoints 
Results from surrogate endpoints generally accrue more quickly than final endpoints, thus allowing for 
clinical trials with shorter follow-up periods and smaller sample sizes.20 Reducing trial sample size and 
duration ensures faster patient access to new therapies and means that trials are also less expensive, 
which make surrogate endpoints attractive to manufacturers or research sponsors alike. This 
efficiency can be illustrated in the setting of cardiovascular disease, where the most common final 
patient-relevant endpoints are mortality and major cardiovascular morbidity (e.g. myocardial infarction, 
stroke, and hospitalisation due to angina). However, the rates of these final outcomes are typically 
low, particularly in populations with early-stage cardiovascular disease, thus requiring a definitive trial 
involving thousands or tens of thousands of patients followed up for several years. In contrast, a trial 
powered on a surrogate primary endpoint (e.g. carotid artery intima-media thickness, luminal loss) 
might involve a few hundred patients followed up for weeks or months.21 Primary endpoints are often 
discrete whereas surrogates are usually continuous and often repeatedly measured, thus providing 
more statistical power to detect significant treatment effects.22 However, it is important to note that 
smaller sample sizes restrict the likelihood of identifying safety issues (especially if they are rare). It 
has been stated that ³WKHUHLVQRVXUURJDWHIRUVDIHW\´23 meaning that usually long-term observations 
of the adverse events of interest are needed to fully characterise the safety profile of therapies.  
There may also be circumstantial and ethical reasons for the use of surrogate endpoints in clinical 
trials of new and emerging treatments - the seriousness of the condition, the availability of alternative 
therapies or the difficulty of studying the final endpoint could influence the acceptability of a surrogate 
endpoint.2,23 At the end of the last century, when the AIDS epidemic was a global concern, hastening 
decision-making about the efficacy of new therapies for HIV infection because of lack of clinical 
benefit data was criticised and discouraged.24 Also, in the case of many treatments developed for rare 
diseases, the use of surrogate endpoints allow registration clinical trials to achieve the accelerated 
approval pathway for drug adoption.25 
 
To date, most of the focus on the use of surrogate endpoints in healthcare policy making has been in 
the context of licensing or market authorisation by centralised agencies, including the FDA and EMA. 
In 1996, the FDA introduced Subpart H, a special regulatory mechanism for drug development 
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programmes, which allows the organisation to grant marketing approval for new drugs for which well-
controlled clinical trials have shown an effect on a surrogate endpoint WKDWLV³UHDVRQDEO\OLNHO\EDVHG
RQHSLGHPLRORJLFDOWKHUDSHXWLFSDWKRSK\VLRORJLFRURWKHUHYLGHQFHWRSUHGLFWFOLQLFDOEHQHILW´26 
Applications under Subpart H applications are often candidates for the fast-track programme²an 
accelerated approval programme to expedite the review of interventions for life-threatening diseases 
or those with irreversible morbidity, which has been in place since 1992.2 A recent review showed that 
pivotal trials using surrogate endpoints as their primary endpoint formed the exclusive basis of FDA 
approvals for 91 of 206 (44%) indications for novel therapeutic agents between 2005 and 2012.27 
Surrogate endpoints were used in virtually all trials of agents approved through the accelerated 
approval pathway, most of which were for the treatment of cancer, infectious diseases, and metabolic 
diseases, including cardiovascular disease, diabetes mellitus, and hyperlipidaemia. For the EMA, 
³conditional approval´ and ³approval under exceptional circumstances´ procedures allow marketing 
authorisation to be granted when comprehensive data cannot be provided at the time of the 
submission.28,29 Although these procedures refer primarily to situations when data from randomised 
trials are not available, they also apply when evidence on the final patient-relevant outcome of interest 
is not available. However, the use of intermediate endpoints that are not the final clinical outcomes of 
UHOHYDQFHVKRXOGRQO\EHWKHEDVLVIRUJUDQWLQJDPDUNHWLQJDXWKRUL]DWLRQZKHQWKH\DUH³DJUHHG´WR
be surrogates or to be sufficiently informative by the scientific and regulatory community. 
Another reason why surrogate endpoints may be preferable in registration RCTs is linked to the 
possibility of cross-over DPRQJWULDOV¶DUPVWKDWFRXOGELDVWKHWUHDWPHQWHIIHFWREVHUYHGRQWKHILQDO
outcome (e.g. overall survival). In case of cross-over, surrogate endpoints might be preferred to final 
endpoints to establish the activity of anti-tumoral agents. However, approaches on how to technically 
handle treatment switching bias have been recently reported in the literature30 andIURPDSD\HU¶V
perspective, it is important to consider that a treatment effect that would reflect the sequence of all 
available treatments would still be of value. 
 
3. The case against surrogate endpoints 
The use of surrogate endpoints in clinical trials means that policy makers must extrapolate from these 
findings to estimate the true benefits to patients and health systems, which results in uncertainty 
about the health and economic value of the health technology in question. For example, for a trial 
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assessing the efficacy of statins based on a reduction in LDL-cholesterol, regulatory agencies may 
want to predict what is the corresponding effect in terms of stroke events prevented, whereas HTA 
bodies may want to predict what is the corresponding QALY gain in the relevant population. A key 
pitfall is that surrogate endpoints do not necessarily provide the same answer as final outcomes on 
the combined risk-benefit profile of a health technology. As mentioned earlier, reliance on tumour 
response as a surrogate outcome led to gefitinib initially being licensed for non-small-cell lung cancer, 
but this drug was later found to have no benefit in terms of overall survival and the licence was 
subsequently restricted. The Cardiac Arrhythmia Suppression Trial (CAST) is a more commonly cited 
and more concerning example of surrogate failure. Ventricular arrhythmia was known to be 
associated with almost four times the risk of death related to cardiac complications, particularly 
sudden death.31,32 Two drugs, encainide and flecainide, were found to suppress arrhythmias 
effectively and were approved by the FDA; however, results from CAST later showed that the use of 
these anti-arrhythmic agents was associated with 2·5 times higher mortality in patients with 
asymptomatic or mildly symptomatic ventricular arrhythmia after myocardial infarction.33 Both drugs 
were later re-labelled and became indicated for life-threatening ventricular arrhythmias only.34 
 
Based on this and other examples of surrogate failures for regulatory approvals, in the late 1990s 
Fleming and De Mets illustrated how the use of surrogate endpoints might lead to inappropriate 
conclusions about the risk-benefit profiles of treatments (figure 1).7 Failure of surrogate endpoints may 
occur for various reasons, but it is often difficult to determine which of the mechanisms illustrated in 
figure 1 might underlie the failure. No clear pattern exists between types of failure and different 
diseases, as shown by the following examples. A putative surrogate endpoint may fail because it does 
not lie in the same pathophysiological process that results in the final endpoint (figure 1a); for 
example, using prostate biopsies as a surrogate for death from prostate cancer when biopsy detects 
only latent disease and death is due to aggressive forms of this tumour. Surrogate endpoints may 
also fail because the health technology may affect only the pathway mediated through the surrogate 
endpoint (figure 1b; for example, when encainide or flecainide were used to supress cardiac 
arrhythmias) or only pathways independent of the surrogate endpoint (figure 1c; for example, when 
CD4 counts were used as potential surrogate endpoints for death from HIV infection). In each case, 
the treatment effect observed on the surrogate endpoint would capture only part of the whole effect on 
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the final endpoint. As a result, a false-positive conclusion (ie, the technology is effective when it is not) 
or a false-negative conclusion (ie, the intervention is not effective when it is) may occur based on 
observations of the surrogate endpoint. The intervention itself may also affect the final outcomes 
through unintended, unanticipated, and unrecognised mechanisms of action that operate 
independently from the disease process (figure 1d). For example, rosiglitazone was approved in 1999 
by the FDA and in 2000 by the EMA as an oral combination therapy for patients with type 2 diabetes 
on the basis that it reduced levels of glycated haemoglobin,35 but it was later found to increase 
significantly the risk of myocardial infarction and mortality.36,37 Finally, in some situations, the 
surrogate could lie in the only causal pathway of the disease process and thus would entirely capture 
WKHLQWHUYHQWLRQ¶VHIIHFW on the final outcome (figure 1e); however, the treatment effects observed on 
the surrogate endpoint could still yield misleading information in relation to the magnitude of the effect 
of the treatment on the final endpoint, that could be either underestimated or overestimated. 
 
<<figure 1 near here>> 
 
Reliance on trials of a surrogate endpoint has more often shown to substantially overestimate the 
treatment effect of health technologies. This problem was reported by Ridker and Torres after 
reviewing 324 consecutive cardiovascular trials.38 They observed that trials with primary endpoints 
that were surrogates were more likely to report a positive treatment effect (77/115 trials, 67%) than 
trials that reported final patient-relevant primary outcomes (113/209 trials, 54%) (p=0·02). A meta-
epidemiological study involving 185 randomised controlled trials that used surrogate endpoints or 
patient-relevant outcomes and that were reported in six high-impact general medical journals was 
specifically designed to confirm or refute this observation by comparing the treatment effects from the 
trials that used surrogates and those that used final outcomes.39 This analysis found that trials that 
used surrogate endpoints were twice as likely to report positive treatment effects as trials that 
reported final outcomes (52/84 trials, 62% vs 37/101 trials, 37%, p<0·01). Furthermore, trials that 
used surrogates found treatment effects that were, on average, 28±48% larger than trials that used 
corresponding final outcomes. This ³surrogate endpoint bias´ was not explained by differences 
between the two groups of trials in terms of the risk of bias or other characteristics.  
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How do we appropriately select, validate, and apply surrogates? 
The potential failure of surrogate endpoints means that the validity of the relation between the 
surrogate and the final outcome needs to be established clearly in advance. Several authors have 
described a variety of statistical methods to validate surrogates.40 However, the complexity of many of 
these statistical methods means that their uptake in practice is relatively low. Below we describe a 
three-step process to validate and use surrogate-based evidence for use in healthcare decision 
making. 
 
1. Establish the level of evidence²The first step in the process is to consider the hierarchy of 
available evidence. Table 2 shows a three-step framework for healthcare policy makers to consider 
the suitability of surrogates, which was proposed by a previous article6 based on the publication by 
Bucher and colleagues.41 In this framework, level 3 evidence for a surrogate is based on biological 
plausibility alone, while evidence is considered to be level 2 when a strong association exists between 
the surrogate and the final endpoint across cohorts or at the level of the individual patient. However, 
as Fleming and DeMets noted, ³a correlate does not a surrogate PDNH´,7 so associations at the level 
of the individual patient do not directly validate surrogate measures, although they may identify good 
prognostic markers.42,43 The highest level of evidence (level 1) therefore relates to evidence showing 
that technologies that improve the surrogate also improve the final outcome across many randomised 
controlled trials. Trial-based evidence of a final outcome is usually not available for a new healthcare 
technology for which surrogate endpoints are used, so this evidence needs to be sourced from other 
trials of the same or a similar technology²for example, in the case of drugs, trials should be of drugs 
from within the same class or, if that is not is available, a different class. This element highlights the 
importance of the specificity of the surrogate outcome validity, in relation to the treatment, to the 
indication and to the context of the proposed use.44 
 
<<table 2 near here>> 
 
When searching for the evidence supporting the link between a putative surrogate and a related final 
outcome, it important to recognise that the surrogacy status of a biomarker is likely to be specific to 
the context of its use and to the intervention.45 Several authors have emphasised that the validity of a 
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surrogate endpoint shown in a particular intervention cannot be assumed to apply to another class, 
particularly when the two have different off-target effects profiles.41,46,47 Furthermore, the use of active 
or inactive control interventions may also influence the surrogate to final outcome relationship.48,49 
Finally, contextual or environmental factors may play a role, for example, a recent evaluation of 
sputum culture results during treatment as potential surrogate endpoints for long-term outcome in 
pulmonary tuberculosis found different results when separate analysis on trials from two geographical 
regions (i.e., East Africa and East Asia) were performed.50  
 
2. Assess the strength of association²Having established the level of evidence, the second step is to 
assess the strength of the association between the surrogate and the final outcome. Among several 
approaches to address this issue, regression-based and meta-analytic approaches dominate the 
field.43 Establishing the strength of an association for level 1 surrogacy usually requires a meta-
analysis of all randomised controlled trials on the subject of interest. The most reliable approach is to 
perform a meta-analysis using patient-level data from all randomized trials of this treatment.51 When 
patient-level data are available, two levels of association can be estimated: the association between 
the surrogate and the final outcome, and the association between the effect of treatment (drug or 
technology) on the surrogate and the final outcome.52 For example, the strength of the association 
between treatment effects on the surrogate (e.g. mean difference) and final (e.g. log odds ratio) 
outcome is usually quantified through the correlation coefficient or its square (called the coefficient of 
determination), both of which range from 0 to 1·0. Thresholds set to identify good surrogates can be 
as high as 0·8 for correlation coefficients (r RUȡor 0·65 for coefficients of determination (R2),53 which 
are particularly strict rules for the acceptability of putative surrogate endpoints when applied in 
practice. Whilst ideally level 1 evidence should be used to establish the surrogacy status of a 
biomarker, it may be that only level 2 evidence is available.19,54 If so, policy makers should take into 
account the greater uncertainty with observational evidence in making their decisions. 
 
3. Quantify the relation between the surrogate and the final outcome²The final step relates to 
predicting and quantifying the relation between the surrogate and the final outcome, and between the 
observed effect on the surrogate and the expected effect on the final outcome. For cost-effectiveness 
analyses, these would be the expected impact on QALYs. A quantitative approach has been 
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proposed to support this objective, using an extension of the meta-analytic approach to surrogate 
DVVHVVPHQW7KHDSSURDFKFRQVLVWVRIHVWLPDWLQJWKH³VXUURJDWHWKUHVKROGHIIHFW´ZKLFKLVWKH
magnitude of treatment effect on the surrogate that would predict a statistically significant treatment 
effect, or with appropriate extension a clinically meaningful effect, on the final outcome (see Technical 
Appendix A).55 Estimating the expected effect on the final outcome is useful to decide whether a 
surrogate endpoint is of practical interest or not. This is the case, e.g., of progression-free survival, 
that is the time elapsed between randomization (or treatment initiation) and documented tumour 
progression or death. Tumour progression is preferably determined by radiographic evidence, but in 
some cases worsening of symptoms and signs of disease may also constitute evidence of 
progression. In gastric cancer, progression-free survival is not an acceptable surrogate for overall 
survival in advanced disease; indeed, the surrogate threshold effect suggests that only very large 
effects on progression-free survival are likely to predict significant effects on overall survival.56 On the 
other hand, the use of progression-free survival as a surrogate endpoint may be limited by the fact 
that progression may have different implications in different settings, according to whether it is 
symptomatic, whether salvage therapy is available, and whether its occurrence heralds imminent 
death. Estimating the expected effect on the final outcome is also crucial for decisions on coverage 
and reimbursement for health technologies. Regulators are usually focused on early evidence of 
safety and efficacy to determine if the balance of benefits and risk is positive when informing the 
design of registration trials, while reimbursement agencies usually consider long-term effectiveness or 
cost-effectiveness. In this step, therefore, not only is the direction and significance of the treatment 
effect important, but also its magnitude.57 Decisions around market access and reimbursement are 
normally based on an assessment of the incremental value of the technology in question for the final 
outcome relative to that for the existing usual or standard of care. In many settings, including the UK, 
Sweden, Australia, and Canada, an assessment of value is formalised in a cost-effectiveness 
analysis.58 It has been estimated that 27% to 50% of all submissions to NICE in the UK, the 
Pharmaceutical Benefits Advisory Committee in Australia, and the Common Drug Review in Canada 
are based on surrogate endpoints.58 Whether decisions on market access and reimbursement are 
based on a formal economic evaluation or on the magnitude of the clinical benefit, the effect of the 
treatment on the surrogate endpoint needs to be large enough to predict an improvement in the final 
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outcome (i.e. length or quality of life) before the technology can be concluded to be of value to 
patients and healthcare systems.  
 
Figure 2 provides a schema showing how to apply this three-step surrogate validation framework to a 
hypothetical assessment of an antihypertensive drug (e.g. a beta-blocker) or device (e.g. renal 
denervation therapy). Looking at many trials of antihypertensive drugs, a meta-regression analysis 
has been undertaken to allow conclusions to be drawn about the strength of the association between 
the reduction in blood pressure (surrogate) and adverse (final) outcome.46 Although not based on this 
meta-analysis, previous economic analyses that modelled the reduction in cardiovascular risk from 
the observed effect of treating blood pressure have shown that antihypertensive drug treatments have 
an excellent cost-effectiveness profile.59,60  
 
<<figure 2 near here>> 
 
How do current surrogate endpoints measure up? 
To date, few empirical assessments have investigated the adequacy of evidence for specific 
surrogate endpoints or groups of surrogates, particularly in terms of reimbursement policy. A timely 
example is with the use of sustained virological response (SVR) for the approval of new direct-acting 
antiviral agents (i.e., boceprevir and telaprevir) in chronic hepatitis C. The FDA has considered SVR 
at 12 weeks a valid surrogate for a primary endpoint in clinical trials based on observational cohorts 
only showing strong correlations between SVR and multiple clinically important outcomes, such as 
development of hepatocellular carcinoma, end-stage liver complications, and mortality.54 
Reimbursement agencies currently lack the necessary evidence to confirm the relationship between 
treatment effects observed on SVR and final outcomes in chronic hepatitis C. 61 On the other end, 
oncology has a long tradition of using surrogates.62-65 Two frequently used surrogates for overall 
survival are progression-free survival and time to progression. Progression-free survival is a 
composite endpoint for which the events of interest are documented tumour progression or death. For 
time to progression, patients with no prior documentation of disease progression are censored at the 
time of death. In the past decade, results of a number of meta-analyses of randomised controlled 
trials quantifying the statistical association between progression-free survival or time to progression 
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and overall survival in cancer have been published. Based on a systematic review of these meta-
analyses, Ciani and colleagues recently sought to assess the suitability of and quality of evidence for 
progression-free survival and time to progression as surrogates for advanced solid tumours.53 
Although the highest evidence was level 2 in less prevalent diseases such as brain tumour, level 1 
evidence had consistently supported some level of association between effects of treatment on both 
progression-free survival and time to progression compared with overall survival in the four most 
frequently evaluated advanced solid tumours: colorectal cancer, non-small-cell lung cancer, breast 
cancer, and ovarian cancer. However, with few exceptions, the strength of the associations between 
the surrogates and final outcome tended to be relatively low, with ȡ<0·7 across tumour types. This 
finding of low levels of associations between surrogate endpoints and survival in oncology was also 
confirmed by Prasad and colleagues.66  
Even if the evidence is considered to be level 1, a low strength of association between the surrogate 
and the final outcome can have important implications for decision making. Two specific tools have 
recently been developed to operationalise components of the three-stage validation framework 
described above and to help policy makers make appropriate choices when selecting surrogate 
endpoints. The first of these tools, the Biomarker Surrogacy Evaluation Schema (BSES3),46 is based 
on a validation scheme originally developed by clinicians and researchers working in rheumatology.67 
The second tool, another framework for the validation of surrogate endpoints in oncology, was 
published in 2011 by the Institute of Quality and Efficiency in Healthcare (IQWiG)²a health 
technology assessment agency that assesses the benefits and harms of drug and non-drug 
technologies on behalf of the German Federal Joint Committee and Federal Ministry of Health.68 For a 
surrogate to be deemed acceptable for reimbursement, both the IQWiG and BSES3 tools require a 
high level of association with the final outcome (i.e. ȡā52ā. Accordingly, only progression-
free survival in metastatic colorectal and ovarian cancer treated with cytotoxic agents would be judged 
to have achieved acceptable evidence of surrogacy.  
 
That progression-free survival and time to progression have been shown to perform poorly as 
surrogates in oncology does highlight a more general current scepticism by payers about using 
surrogates in their coverage decisions.69 This view was reflected in WKHJXLGHOLQH³(QGSRLQWVXVHGLQ
UHODWLYHHIIHFWLYHQHVVDVVHVVPHQWRISKDUPDFHXWLFDOV´published by the European Network for Health 
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Technology Assessment (EUnetHTA) in February 2013,70 which recommended that European health 
technology appraisal agencies should be very cautious about using surrogates and should use them 
only if they have been appropriately validated according to approaches recognised for evaluation of 
surrogates. This caution was echoed in 1,&(¶VPRVWUHFHQWXSGDWHRIJXLGDQFH on methods for 
manufacturers to which our work contributed. This guidance now requires a review of the evidence to 
support the validity of the surrogate endpoint, a clear description of how the relationship between the 
surrogate and final outcome has been quantified in an economic model, and a full exploration of the 
additional uncertainty associated with using surrogates to predict cost-effectiveness (e.g. a 
probabilistic sensitivity analysis that explicitly considers the uncertainty of the predicted treatment 
effect on the final outcome given the observed treatment effect on the surrogate).71 It is important to 
note that where cost-effectiveness informs reimbursement decisions, the problem of using surrogates 
in economic models is often only one aspect of missing or incomplete data. For example, the 
collection of a final outcome, but only in the short term, requires extrapolation to assess the long-term 
effect on the final outcome which has its own pros and cons. Hence, the framework presented here 
represents only one aspect of what is often a chain of evidentiary uncertainties that need to be 
considered to make sense of the available evidence and estimate the incremental cost-effectiveness 
ratio. 
 
Unanswered questions and areas for future research 
In this Review, we have sought to bring together key evidence for and against the use of surrogate 
endpoints. Although we have shown that the use of surrogates for healthcare policy making can be 
problematic, we also argue that, when selected and used appropriately, they can not only offer 
important opportunities for the more efficient conduct of clinical trials but also allow faster access to 
new health technologies, which would benefit patients and healthcare systems. Based on knowledge 
of epidemiology, clinical trials, and statistical methods, we have outlined a three-step framework to 
guide the selection of surrogate endpoints by policy makers. However, some unanswered questions 
remain, and these present opportunities for further methodological research to inform future handling 
of surrogates. 
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Do we need individual patient-level data to fully validate surrogates?²For practical reasons, trial-level 
(or aggregate) data are the usual evidence available for policy making around coverage and 
reimbursement given the costs and constraints of gathering multi-trial datasets-some of which belong 
to corporate sponsors. However, trial-level data are inadequate to perform gold standard analyses of 
surrogacy.52,55 Published reports may provide unreliable or biased summary statistics (e.g. results on 
a non-intervention-to-treat population, or reporting of odds ratio rather than hazard ratio for time to 
event data). Most aggregate-data analyses fail to take into account estimation error (i.e. a finite 
number of finite-sample-size trials in the meta-analytic data) by using ³HUURUV-in-YDULDEOHV´UHJUHVVLRQ
models, or use only simple linear regression models, irrespective of the functional form of the data. 
Access to patient-level data is desirable but should be further encouraged by data sharing and data 
transparency initiatives led by both the European Medicines Agency and the pharmaceutical 
industry.72-74  
 
How can we improve the quality of the future evidence base for surrogates?²As outlined above, 
validation of a surrogate endpoint is rather a chicken-and-egg problem, in that it requires evidence of 
the relation between the surrogate and the final outcome. As the final outcome for a specific new 
technology will not yet be available²and hence the surrogate is used as replacement²trials of older 
technologies in the same technology class are often used to provide that evidence. However, moving 
forward, there is a unique opportunity to link the coverage and licensing of technologies based on 
surrogate endpoints to a conditional decision75,76 that incentivises extension of follow-up in order to 
accrue the relevant evidence on final outcomes to inform later and more definitive decisions on 
coverage. In-depth knowledge of the natural history of diseases combined with analyses on existing 
baseline data, emerging large data networks or past trials helps to identify surrogate endpoints, 
WKURXJKDSURFHVVWKDWZLOOHQDEOHWKHIDVWGHYHORSLQJIUDPHZRUNRIPHGLFLQH¶VDGDSWLYHSDWKZD\VWR
patients (MAPPs).77,78 
 
How can we improve the uptake of surrogate validation frameworks into policy making?²We have 
described a three-stage framework for the use of surrogates in policy making, and a small number of 
existing tools68,79 are available to guide the use of surrogates. However, currently little or no evidence 
is available around their acceptability and the likelihood of their uptake by key stakeholders in the 
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healthcare policy-making process, including payers, patient groups, industry, and clinicians.80 
Heterogeneous approaches to validation of surrogates also lead to decisions on reimbursement that 
often vary across agencies and diseases, which poses an issue of equity of access for patients 
across different jurisdictions.81 Rocchi et al. compared acceptance of surrogates, from hemoglobin 
A1c to sustained virological response, for the approval of thirteen drugs across seven international 
regulatory and HTA authorities showing high variability in consideration and assessment of surrogate 
endpoints. An analogue comparison was performed across three major EU countries on six products 
approved in type 2 diabetes, hepatitis C and oncology.82 The analysis concluded that IQWiG was 
more often inclined to recognize no or non quantifiable benefit for the medicines under assessment 
compared to the French Haute Autorité de Santé, where request of prospective or observational 
additional studies is likely, or NICE and the Scottish Medicines Consortium, where however low 
surrogate to final outcomes associations lead to highly uncertain incremental cost-effectiveness 
ratios. Research is therefore urgently needed to better understand the barriers to implementation of 
surrogate evaluation tools and harmonisation of different approaches, particularly across the current 
licensing and reimbursement divide.  
 
How can we improve the use and reporting of surrogates in clinical trials? ²There are also important 
implications for use and reporting of surrogates for the clinical-trials community. A review of 
randomised controlled trials published in high-impact general medical journals showed that 43% of 
authors do not explicitly state that their primary outcome was a surrogate endpoint and only a third of 
publications discuss the potential limitations of the surrogate endpoint or evidence about its validity.83 
Reports of clinical trials should therefore state whether their collected outcomes are surrogate 
endpoints and provide a clear rationale for the selection of these surrogates, including reference to 
biological plausibility and evidence of validation. It has been suggested that guidance on surrogates 
should be incorporated into the current Consolidated Standards of Reporting Trials (CONSORT) 
statement.83  
 
Conclusions 
The potential for surrogate endpoints to impact on healthcare policy and the consequent diffusion of 
technologies into practice is illustrated by the fact the primary outcome of more than 40% of pivotal 
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trials used as the basis for approval of new indications is a surrogate that aims to substitute for and 
predict a final patient-relevant outcome.27 In the case of specific diseases, such as oncology, this 
proportion increases to two thirds of all trials. In terms of reimbursement decisions, a substantial 
proportion of all submissions to the main HTA agencies are based on surrogate endpoints.58 With 
increasing societal pressure for faster access to therapies, the use of surrogates in healthcare policy 
is likely to increase. The recent data sharing initiatives will greatly facilitate the evaluation of 
surrogates using patient-level data from industry-sponsored randomized clinical trials. 
 
Relying on surrogates rather than final patient-relevant outcomes increases the uncertainty when 
making decisions about licensing and coverage of healthcare technologies. Furthermore using 
putative surrogates that are not validated may raise serious ethical concerns. Surrogates can result in 
market access for technologies that turn out to offer no true health benefit²or even harm²to patients 
and can result in overestimation of treatment effects, which can lead to inappropriate decisions on 
coverage. However, the use of appropriately validated surrogate endpoints provides an unmissable 
opportunity to speed up access to innovative technologies that offer important benefits for patients 
and healthcare systems and to improve efficiency within the research and development environment.  
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Figure 1: Illustrations of different mechanisms for failure of surrogate endpoint  
Adapted from Fleming and DeMets7 
 
a) The surrogate is not in the causal pathway of the disease process; b) Of several causal pathways 
of disease, the health technology only affects the pathway mediated through the surrogate; c) The 
VXUURJDWHLVQRWLQWKHSDWKZD\RIWKHKHDOWKWHFKQRORJ\¶VHIIHFWRU LVLQVHQVLWLYHWRLWG7KHKHDOWK
technology has mechanisms of actions independent of the disease process (dotted line); e) The 
surrogate lies in the only causal pathway of the disease process, however, the treatment effect 
observed on the surrogate endpoint could underestimate or overestimate the treatment effect on the 
final outcome. 
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Figure 2: Framework for the evaluation of surrogate endpoints in a health technology assessment setting  
HRQoL = health related quality of life 
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The graph shows the sequence of actions to implement in a health technology assessment of a drug technology when surrogate outcomes evidence is 
available. For example, systolic blood pressure is the surrogate endpoint for a major cardiovascular event (e.g. a stroke) and, in a cost-effectiveness 
evaluation, for health-related quality of life (HRQoL) and mortality. After an initial scope of the decision problem, the first step requires systematic review of 
the evidence explaining the relationship between the surrogate outcome and the final patient relevant outcome (establish the level of evidence). A level-2 
evidence would show that groups of patients with higher average blood pressure have worse cardiovascular outcomes. A level-1 evidence would show that 
treatment-induced changes on the surrogate (i.e. reduction in blood pressure), would correspond to treatment-induced changes on the final outcome (i.e. a 
reduction in stroke events). This evidence will then be assessed to define whether the surrogate is associated with and predictive of the final patient relevant 
outcome (validation). If so, a quantification of the estimated effect on the final outcome given the observed effect on the surrogate outcome in the setting of 
interest will be performed (quantification), and could be used as input in a cost-effectiveness analysis. 
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Table 1: Outcome and endpoint definitions 
Adapted from Biomarkers Definition Working Group5 
Endpoint Definition* Example (Diabetes 
mellitus) 
Example (Cardiovascular 
disease) 
Biomarker Characteristic that is objectively 
measured and evaluated as an indicator 
of normal biological processes, 
pathogenic processes, or pharmacologic 
responses to therapeutic intervention  
HbA1C, C-peptide LDL-cholesterol, C-reactive 
protein, cardiac troponins 
Patient-relevant 
(final) endpoint 
Characteristic or variable that reflects 
how patient feel or function or how long 
they survive 
Diabetic foot 
mortality, health-related 
quality of life 
Stroke, myocardial infarction 
mortality, health-related 
quality of life 
Intermediate 
endpoint 
Endpoint is, or is felt to be, of value to 
patients but does not represent the 
ultimate patient-relevant final outcome 
of interest 
Hypoglycemic 
symptoms  
Exercise capacity 
Surrogate endpoint Biomarker or intermediate endpoint 
intended to substitute and predict for 
patient-relevant final endpoint 
HbA1c and glucose 
control as surrogate for 
diabetes complications 
SBP as surrogate for major 
cardiovascular events in 
patients with hypertension 
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and mortality 
HbA1C=glycated haemogolobin, LDL-cholesterol=low-density lipoprotein cholesterol, SBP=systolic blood pressure 
*Definitions adapted from the Biomarkers Definition Working Group5 
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Table 2: Hierarchy of evidence for surrogate endpoint validity 
Adapted from Elston and Taylor6 and Bucher and colleagues41  
Hierarchy level Requirement Source of evidence 
1 Treatment effect on surrogate 
corresponds to treatment 
effect on final outcome 
Randomised controlled trials 
showing that changes in the 
surrogate are associated with 
commensurate changes in 
the final outcome 
2 Consistent association 
between surrogate and final 
outcome 
Epidemiological/observational 
studies 
3 Biological plausibility of 
relation between surrogate 
and final outcome 
Pathophysiological studies 
and understanding of the 
disease process 
 
